Skip to content
Sepofarsen
Sepofarsen is an oligonucleotide pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Leber congenital amaurosisD057130Orphanet_65H35.52424
Neurologic manifestationsD0094611323
Retinal diseasesD012164HP_0000479H35.91323
Vision disordersD014786HP_0000505H53.111323
Eye diseasesD005128EFO_0003966H441323
BlindnessD001766HP_0000618H53.121323
Hereditary congenital and neonatal diseases and abnormalitiesD0093581323
Sensation disordersD012678H02.591323
Hereditary eye diseasesD0157851212
Retinal degenerationD012162HP_0001105111
Show 1 more
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSEPOFARSEN
INNsepofarsen
Description
Sepofarsen is an oligonucleotide pharmaceutical. It is currently being investigated in clinical studies.
Classification
Oligonucleotide
Drug classantisense oligonucleotides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL4594497
ChEBI ID
PubChem CID
DrugBank
UNII ID7CAZ46X8EL (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 47 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details